Award
NIH Reporter #5R01AI183405-03
Treatment of isoniazid-resistant tuberculosis: closing evidence gaps on safety, effectiveness, and pharmacokinetics of the standard regimen
Recipient
SOCIOS EN SALUD SUCURSAL PERU
Award Amount
$132,182.00
Ceiling
$132,182.00
Awarded
July 07, 2026
Identifier
5R01AI183405-03
The study will assess the safety and effectiveness of the 6Lfx-REZ regimen for isoniazid-resistant, rifampicin-sensitive tuberculosis in Peru, and examine levofloxacin and rifampicin drug levels to inform treatment dosing.
Description
Research to evaluate the safety, tolerability, effectiveness, and pharmacokinetics of the standard regimen for isoniazid-resistant tuberculosis.